Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase
Cancer · 2024
DOI: 10.1002/cncr.35384 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2024. Verfasst von Fadi G Haddad und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Pyridazines, Imidazoles, Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: ARIAD Pharmaceuticals, Inc. (later acquired by Takeda), Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Background
Ponatinib is a third‐generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with robust activity in Philadelphia chromosome–positive leukemias. Herein, we report the long‐term follow‐up of the phase 2 trial of ponatinib in chronic myeloid leukemia in chronic phase.
Methods
Patients received ponatinib 30 to 45 mg/day. The primary end point was the rate of 6‐month complete cytogenetic response (CCyR). The study was held in June 2014 because of the risk of cardiovascular toxicity, requiring patients to change TKI.
Results
Fifty‐one patients were treated with ponatinib (median dose, 45 mg/day). Median age was 48 years (range, 21–75); 30 (59%) had baseline cardiovascular comorbidities. Median treatment duration was 13 months (range, 2–25). Fourteen patients (28%) discontinued ponatinib because of toxicities, 36 (71%) after the Food and Drug Administration warning/study closure, and one for noncompliance. Dasatinib was the most frequently chosen second‐line TKI ( n = 34; 66%). Among 46 patients evaluable at 6 months, 44 (96%) achieved CCyR, 37 (80%) major molecular response, 28 (61%) MR4, and 21 (46%) MR4.5. The cumulative 6‐month rates of CCyR, major molecular response, MR4, and MR4.5 were 96%, 78%, 50%, and 36%, respectively. Durable MR4 ≥24 or ≥60 months was observed in 67% and 51% of patients, respectively. The 24‐month event‐free survival rate was 97%. After a median follow‐up of 128 months, the 10‐year overall survival rate was 90%. Eight patients (16%) had serious grade 2 to 3 cardiovascular adverse events, leading to permanent discontinuation in five (10%).
Conclusion
Ponatinib yielded high cytogenetic and molecular responses in newly diagnosed chronic myeloid leukemia in chronic phase. Its use in the frontline setting is hindered by arterio‐/vaso‐occlusive and other severe toxicities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
- Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
- Department of Clinical Hematology and INSERM U1052, CRCL, Centre Leon Bérard, Lyon, France.
ORCID-Profile: Fadi G Haddad, Koji Sasaki, Lewis Nasr, Nicholas J Short, Tapan Kadia, Franck E Nicolini, Elias Jabbour, Hagop Kantarjian
Förderung
- ARIAD Pharmaceuticals, Inc. (later acquired by Takeda)
- Takeda Pharmaceutical Company
Zitieren
APA
Haddad, F. G., Sasaki, K., Nasr, L., Short, N. J., Kadia, T., Dellasala, S., Cortes, J., Nicolini, F. E., Issa, G. C., Jabbour, E., & Kantarjian, H. (2024). Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. https://doi.org/10.1002/cncr.35384
Vancouver
Haddad FG, Sasaki K, Nasr L, Short NJ, Kadia T, Dellasala S, et al. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer. 2024. doi:10.1002/cncr.35384
BibTeX
@article{Haddad2024,
author = {Haddad, Fadi G and Sasaki, Koji and Nasr, Lewis and Short, Nicholas J and Kadia, Tapan and Dellasala, Sara and Cortes, Jorge and Nicolini, Franck E and Issa, Ghayas C and Jabbour, Elias and Kantarjian, Hagop},
title = {Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35384}
}
EUVIMED